Search results
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 9 hours agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 14 hours agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-
...Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles...
Fairfield-Suisun Daily Republic· 4 days agoAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced ...
The doctor behind the next big thing in cancer treatment
CNN via AOL· 4 days agoDr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 5 days agoLater this month, the Food and Drug Administration will consider approving Moderna...in babies and...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 6 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...
Calliditas' survival data salvage midphase cancer trial after primary endpoint miss
FierceBiotech· 7 days agoCalliditas Therapeutics had a typical to-do list for its midphase head and neck cancer study. Step...
2 No-Brainer Dividend Stocks to Buy in May
Motley Fool via Yahoo Finance· 5 days agoThe oncology market is known for its strong pricing power, with cancer drugs typically carrying high price tags and significant margins. While Pfizer's...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
WKBN 27 Youngstown· 7 days agocancer targeted mid-year 2024Targeting initial Phase 2 expansion for IDE161 in HRD solid tumors and Phase 1 FPI for IDE161 in combination with Merck's anti-PD-1 therapy < ...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 14 hours agoAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer< ...